Gamma-Tocopherol and Docosahexaenoic Acid Decrease Inflammation in Dialysis Patients

Journal of Renal Nutrition

Volumn 17, Issue 5, 2007, Pages 296-304

  Himmelfarb, Jonathan ^a,b   Phinney, Stephen ^c   Ikizler, T Alp ^d   Kane, Jane ^b   McMonagle, Ellen ^b   Miller, Guy ^e  

^a MAINE MEDICAL CENTER   (United States)

^b Maine Medical Center Research Institute   (United States)

^c Galileo Laboratories Inc   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BioElectron Technology Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; GAMMA TOCOPHEROL; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD; CHEMISTRY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; INFLAMMATION; MALE; MASS FRAGMENTOGRAPHY; MIDDLE AGED; OXIDATIVE STRESS; PHOTOMETRY; PROTEIN CARBONYLATION; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHROMATOGRAPHY, GAS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; F2-ISOPROSTANES; FEMALE; GAMMA-TOCOPHEROL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 34548035398     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2007.05.011     Document Type: Article

References (46)

1. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 Suppl (1998) S112-S119
2. Kalantar-Zadeh K., Block G., Humphreys M.H., and Kopple J.D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63 (2003) 793-808
3. Albert M.A., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
4. Chang J.W., Yang W.S., Min W.K., Lee S.K., Park J.S., and Kim S.B. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39 (2002) 1213-1217
5. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., and Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
6. van den Akker J.M., Bredie S.J., Diepenveen S.H., van Tits L.J., Stalenhoef A.F., and van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 16 (2003) 238-244
7. Usberti M., Gerardi G., Bufano G., et al. Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients. Am J Kidney Dis 40 (2002) 590-599
8. Boaz M., Smetana S., Weinstein T., et al. Secondary Prevention With Antioxidants of Cardiovascular Disease in End-Stage Renal Disease (SPACE): randomised placebo-controlled trial. Lancet 356 (2000) 1213-1218
9. Tepel M., van der Giet M., Statz M., Jankowski J., and Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a controlled trial. Circulation 107 (2003) 992-995
10. Galli F., Floridi A.G., Floridi A., and Buoncristiani U. Accumulation of vitamin E metabolites in the blood of renal failure patients. Clin Nutr 23 (2004) 205-212
11. Himmelfarb J., Kane J., McMonagle E., et al. Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int 64 (2003) 978-991
12. Smith K.S., Lee C.L., Ridlington J.W., Leonard S.W., Devaraj S., and Traber M.G. Vitamin E supplementation increases circulating vitamin E metabolites tenfold in end-stage renal disease patients. Lipids 38 (2003) 813-819
13. Galli F., Buoncristiani U., Conte C., Aisa C., and Floridi A. Vitamin E in uremia and dialysis patients. Ann. N Y Acad Sci 1031 (2004) 348-351
14. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., and Roberts L.J. A series of prostaglandin F2-like compounds are produced in vivo by humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 87 (1990) 9383-9387
15. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37 (1959) 911-917
16. Raatz S.K., Bibus D., Thomas W., and Kris-Etherton P. Total fat intake modifies plasma fatty acid composition in humans. J Nutr 131 (2001) 231-234
17. Pupim L.B., Himmelfarb J., McMonagle E., Shyr Y., and Alp I.T. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 65 (2004) 2371-2379
18. Dupont W.D., and Plumer W.D. PS power and sample size program available for free on the internet. Controlled Clin Trials 18 (1997) 274
19. Bologa R.M., Levine D.M., Parker T.S., et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32 (1998) 107-114
20. Gunnell J., Yeun J.Y., Depner T.A., and Kaysen G.A. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33 (1999) 63-72
21. Sitter T., Bergner A., and Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 15 (2000) 1207-1211
22. Trey J.E., and Kushner I. The acute phase response and the hematopoietic system: the role of cytokines. Crit Rev Oncol Hematol 21 (1995) 1-18
23. Jiang Q., Elson-Schwab I., Courtmanch C., and Ames B.N. g-Tocopherol and its major metabolite, in contrast to a-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci U S A 97 (2000) 11495-11499
24. Jiang Q., Lykkesfeldt J., Shigenaga M.K., Shigeno E.T., Christen S., and Ames B.N. Gamma-tocopherol supplementation inhibits protein nitration and ascorbate oxidation in rats with inflammation. Free Radic Biol Med 33 (2002) 1534-1542
25. Liu M., Wallmon A., Olsson-Mortlock C., Wallin R., and Saldeen T. Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms. Am J Clin Nutr 77 (2003) 700-706
26. Grammas P., Hamdheydari L., Benaksas E.J., et al. Anti-inflammatory effects of tocopherol metabolites. Biochem Biophys Res Commun 319 (2004) 1047-1052
27. Hensley K., Benaksas E.J., Bolli R., et al. New perspectives on vitamin E: gamma-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med 36 (2004) 1-15
28. Jiang Q., and Ames B.N. Gamma-tocopherol, but not alpha-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J 17 (2003) 816-822
29. Albert C.M., Campos H., Stampfer M.J., et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 346 (2002) 1113-1118
30. Burr M.L., Fehily A.M., Gilbert J.F., et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 2 (1989) 757-761
31. von Schacky C., Angerer P., Kothny W., Theisen K., and Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 130 (1999) 554-562
32. De Caterina R., Liao J.K., and Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr 71 Suppl (2000) 213S-223S
33. Lukiw W.J., Cui J.G., Marcheselli V.L., et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115 (2005) 2774-2783
34. Bannenberg G.L., Chiang N., Ariel A., et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 174 (2005) 4345-4355
35. Ringbom T., Huss U., Stenholm A., et al. Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod 64 (2001) 745-749
36. Khalfoun B., Gruel Y., Bardos P., and Lebranchu Y. Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human lymphocyte proliferation induced by allogenic cells. Transplant Proc 29 (1997) 2397
37. Dwyer J.H., Allayee H., Dwyer K.M., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350 (2004) 29-37
38. Di M.L., Maffettone A., Cipriano P., et al. Is the erythrocyte membrane fatty acid composition a valid index of skeletal muscle membrane fatty acid composition?. Metabolism 49 (2000) 1164-1166
39. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., and Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukotrienes Essent Fatty Acids 69 (2003) 393-399
40. Felton C.V., Stevenson J.C., and Godsland I.F. Erythrocyte-derived measures of membrane lipid composition in healthy men: associations with arachidonic acid at low to moderate but not high insulin sensitivity. Metabolism 53 (2004) 571-577
41. Bistrian B.R. Clinical aspects of essential fatty acid metabolism: Jonathan Rhoads lecture. J Parenter Enteral Nutr 27 (2003) 168-175
42. Iijima S., Otsuka F., Kikuchi H., et al. Oral supplementation with gamma-linolenic acid extracted from Mucor circinelloides improves the deformability of red blood cells in hemodialysis patients. Nephron 86 (2000) 122-128
43. Tsuzuki D., Sumino K., and Yokoyama M. Analysis of 7-ketocholesterol in low density lipoprotein and fatty acid composition in erythrocyte membranes of patients on maintenance hemodialysis and healthy controls. Clin Chim Acta 295 (2000) 155-168
44. Friedman A.N., Moe S.M., Perkins S.M., Li Y., and Watkins B.A. Fish consumption and omega-3 fatty acid status and determinants in long-term hemodialysis. Am J Kidney Dis 47 (2006) 1064-1071
45. Boaz M., Smetana S., Weinstein T., et al. Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): Randomized placebo-controlled trial. Lancet 356 (2000) 1213-1218
46. Tepel M., van der Giet M., Statz M., et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A controlled trial. Circulation 107 (2003) 992-995